Prognostic features and markers for testicular cancer management

Indian Journal of Urology

Volumn 26, Issue 1, 2010, Pages 76-81

  Leman, Eddy S ^a   Gonzalgo, Mark L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Non seminoma; Prognostic factors; Seminoma; Testicular cancer; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MITOCHONDRIAL DNA; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN CELL DIVISION KINASE 10; PROTEIN KINASE; PROTEIN P53; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CONFERENCE PAPER; EMBRYONAL CARCINOMA; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METASTASIS; ORCHIECTOMY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTIS CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VOLUME;

EID: 77950582720     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.60450     Document Type: Conference Paper

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Shaw J. Diagnosis and treatment of testicular cancer. Am Fam Physician 2008;77:469-474
3. Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277-308.
4. Martin OV, Shialis T, Lester JN, Scrimshaw MD, Boobis AR, Voulvoulis N. Testicular dysgenesis syndrome and the estrogen hypothesis: A quantitative meta-analysis. Environ Health Perspect 2008;116:149-157
5. Dieckmann KP, Endsin G, Pichlmeier U. How valid is the prenatal estrogen excess hypothesis of testicular germ cell cancer? A case control study on hormone-related factors. Eur Urol 2001;40:677-83; discussion 84.
6. Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003;21:1922-1927
7. Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000;24:197-200.
8. Bosl GJ, Ilson DH, Rodriguez E, Motzer RJ, Reuter VE, Chaganti RS. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994;86:349-355
9. Huyghe E, Plante P, Thonneau PF. Testicular cancer variations in time and space in Europe. Eur Urol 2007;51:621-628
10. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: An overview. Int J Cancer 2005;116:331-339
11. von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377-427.
12. Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M. Germ cell tumours of the testis. Crit Rev Oncol Hematol 2005;53:141-164
13. Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000;88:162-168
14. Franco R, Esposito F, Fedele M, Liguori G, Pierantoni GM, Botti G, et al. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours. J Pathol 2008;214:58-64.
15. de Jong J, Looijenga LH. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit Rev Oncog 2006;12:171-203.
16. de Jong J, Stoop H, Dohle GR, Bangma CH, Kliffen M, van Esser JW, et al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol 2005;206:242-249
17. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250
18. de Jong J, Stoop H, Gillis AJ, van Gurp RJ, van de Geijn GJ, Boer M, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 2008;215:21-30.
19. Perrett RM, Turnpenny L, Eckert JJ, O'Shea M, Sonne SB, Cameron IT, et al. The early human germ cell lineage does not express SOX2 during in vivo development or upon in vitro culture. Biol Reprod 2008;78:852-858
20. Leman ES, Magheli A, Yong KM, Netto G, Hinz S, Getzenberg RH. Identification of nuclear structural protein alterations associated with seminomas. J Cell Biochem 2009;108:1274-1279
21. Pectasides D, Papaxoinis G, Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, et al. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1. Anticancer Res 2009;29:737-744
22. Ellinger J, Albers P, Muller SC, von Ruecker A, Bastian PJ. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int 2009;104:48-52.
23. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007;64:182-197
24. Parker C, Milosevic M, Panzarella T, Banerjee D, Jewett M, Catton C, et al. The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance. Eur J Cancer 2002;38:2014-2019
25. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931-1934
26. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 2002;20:4448-4452
27. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, et al. Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005;61:736-740
28. Fossa SD, Jacobsen AB, Aass N, Heilo A, Stenwig AE, Kummen O, et al. How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources? Br J Cancer 1994;70:1156-1160
29. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis: A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 1988;62:1202-1206
30. Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999;83:76-82.
31. Alexandre J, Fizazi K, Mahe C, Culine S, Droz JP, Théodore C, et al. Stage I non-seminomatous germ-cell tumours of the testis: Identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001;37:576-582
32. Wishnow KI, Johnson DE, Swanson DA, Tenney DM, Babaian RJ, Dunphy CH, et al. Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 1989;34:339-343
33. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003;111:76-83; discussion -5.
34. Ondrus D, Hornak M. Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT): A minimum follow-up period of 5 years. Tumori 1994;80:362-364
35. Sturgeon JF, Jewett MA, Alison RE, Gospodarowicz MK, Blend R, Herman S, et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992;10:564-568
36. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988;6:1597-1603
37. Pont J, Holtl W, Kosak D, Machacek E, Kienzer H, Julcher H, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: A prospective trial. J Clin Oncol 1990;8:16-20.
38. Atsu N, Eskicorapci S, Uner A, Ekici S, Güngen Y, Erkan I, et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 2003;92:32-35
39. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995;154:1045-1049
40. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma: Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762-1768
41. Ernst DS, Brasher P, Venner PM, Czaykowski P, Moore MJ, Reyno L, et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 2005;12:2575-2580
42. International germ cell cancer collaborative group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.